Novartis AG to Invest $500 Million in New Singapore Site

Published: Oct 31, 2012

Novartis Pharmaceuticals | Jobs at Novartis Pharmaceuticals

Novartis AG announced today the construction of a new state-of-the-art biotechnology production site in Singapore with an investment valued at over USD 500 million. The new facility will focus on drug substance manufacturing based on cell culture technology. It will be co-located with the pharmaceutical production site based in Tuas, Singapore. In the future, Singapore is expected to be a technological competence center for both biotechnology and pharmaceutical manufacturing at Novartis.

Back to news